Evidence map›Paper›PMID 32203186›Full record

ArticleCellular & molecular immunology2020

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients.

Hong-Yi Zheng, Mi Zhang, Cui-Xian Yang, Nian Zhang, Xi-Cheng Wang, Xin-Ping Yang, Xing-Qi Dong, Yong-Tang Zheng

4 registry-linked trialsAbstract readLetterComment
In one paragraph

Article in Cellular & molecular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 620 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
620citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04390269 unknown statusnot on this map

Various Molecular Markers With Predictive and Prognostic Significance in COVID-19 Outcome

TypeobservationalSponsorMansoura UniversityRan2020 to 2022Enrolled200ConditionsGenetic Predisposition to Disease
NCT04470583 unknown statusnot on this map

Evaluation of Clinical Parameters Following COVID-19 Infection in Pregnancy (COpregVID)

TypeobservationalSponsorChelsea and Westminster NHS Foundation TrustRan2020 to 2021Enrolled116ConditionsCOVID-19, 2019 Novel Coronavirus Infection, COVID-19 Infection
NCT04517162 phase1 / phase2unknown statusnot on this map

Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial

TypeinterventionalSponsorJanette Furuzawa CarballedaRan2020 to 2021Enrolled90ConditionsCovid19, Cytokine Storm, Regulation of Inflammatory Response, Pulmonary FibrosisArmsCollagen-Polyvinylpyrrolidone
NCT04521400 phase2unknown statusnot on this map

the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19

TypeinterventionalSponsorShahid Beheshti University of Medical SciencesRan2020 to 2020Enrolled100ConditionsCovid19ArmsHigh dose Interferon-beta 1a, Lopinavir/Ritonavir, Low dose Interferon-beta 1a
3 · Its place in the literature

Who cites it

620 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Trial
  5. Trial
  6. Article
  7. Renaissance of antiviral CD8Nature reviews. Immunology · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025
    Review
  13. Article
  14. Review
  15. Article
  16. Infectious and Immunological Links Between Periodontitis and COVID-19: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Review

560 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Hong-Yi Zheng *Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China.
Mi Zhang *Yunnan Provincial Hospital of Infectious Diseases, Kunming, 650301, China.
Cui-Xian YangYunnan Provincial Hospital of Infectious Diseases, Kunming, 650301, China.
Nian ZhangYunnan Provincial Hospital of Infectious Diseases, Kunming, 650301, China.
Xi-Cheng WangYunnan Provincial Hospital of Infectious Diseases, Kunming, 650301, China.
Xin-Ping YangYunnan Provincial Hospital of Infectious Diseases, Kunming, 650301, China.
Xing-Qi DongYunnan Provincial Hospital of Infectious Diseases, Kunming, 650301, China. dongxq801@126.com.
Yong-Tang ZhengKey Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650223, China. zhengyt@mail.kiz.ac.cn.ORCID http://orcid.org/0000-0001-5469-0324

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CoronavirusBetacoronavirusChinaCoronavirus InfectionsCOVID-19HumansPandemicsPneumonia, ViralSARS-CoV-2T-Lymphocytes

Identifiers

PMID32203186
PMCPMC7091621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.